Australia invests billions in health research amid global cancer testing disparities

Australia is significantly increasing its investment in health and cancer research. Between 2021 and 2025, the National Health and Medical Research Council (NHMRC) and the Medical Research Future Fund (MRFF) awarded a combined $4.52 billion (AUD 6.46 billion) through 4,012 grants. Additionally, a $7.7 million (AUD 11 million) investment via Cancer Institute NSW aims to improve cancer prevention, detection, and treatment in regional and rural communities, specifically targeting surgical clinical trials and researcher training.

On a global scale, a new commission by The Lancet Oncology has highlighted profound inequalities in access to cancer genetic testing. The report notes that only 2 percent of biomarker-based cancer trials are conducted in low- and middle-income countries, compared to 81 percent in high-income nations. This disparity creates a “paradox of success,” where the rapid expansion of precision oncology increases costs and complexity faster than population-level benefits.

Meanwhile, the global patient experience technology market is projected to grow from $740 million in 2026 to $1.29 billion by 2031. This growth is driven by the adoption of digital-first healthcare services, including AI-enabled engagement, patient portals, and telehealth, as providers seek to improve access and personalized care.